Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(22%)
Results Posted
67%(4 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
3
33%
Ph phase_1
4
44%
Ph phase_2
2
22%

Phase Distribution

4

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Recruiting1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 22 (22.2%)
Phase 33 (33.3%)

Trials by Status

completed667%
recruiting111%
terminated111%
active_not_recruiting111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_3

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735
terminatedphase_2

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

NCT05415410
completedphase_1

A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

NCT05706623
active_not_recruitingphase_3

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

NCT05018286
completedphase_2

Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

NCT04964986
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07742735Phase 3

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

Recruiting
NCT05415410Phase 2

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

Terminated
NCT05706623Phase 1

A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Completed
NCT05018286Phase 3

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

Active Not Recruiting
NCT04964986Phase 2

Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

Completed
NCT04627025Phase 3

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

Completed
NCT06002555Phase 1

Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

Completed
NCT04699032Phase 1

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

Completed
NCT05995704Phase 1

Evaluation of Apraglutide on Gastric Emptying

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9